Virtus Biotech Clinical Trials ETF
BBC
17 hedge funds and large institutions have $8.24M invested in Virtus Biotech Clinical Trials ETF in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
1.22% less ownership
Funds ownership: 32.04% → 30.82% (-1.2%)
6% less funds holding
Funds holding: 18 → 17 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
45% less capital invested
Capital invested by funds: $14.9M → $8.24M (-$6.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
+$668K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$593K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$502K |
| 4 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$56.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$6.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$1.92M |
| 2 |
Jane Street
New York
|
-$783K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$638K |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$262K |
| 5 |
WKWM
Walter & Keenan Wealth Management
Souh Bend,
Indiana
|
-$252K |
BBC Hedge Fund Activity: Q4 2018 in Review
17 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2018, worth a combined $8.24M — down 45% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBC and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Alpine Woods Capital Investors, opening a new position worth an estimated $668K. The largest seller was Advisory Services Network, cutting an estimated $1.92M.
- 17 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2018, down from 18 in Q3 2018.
- Funds reported $8.24M of Virtus Biotech Clinical Trials ETF stock for Q4 2018, down 45% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2018 and 4 closed out, a net change of -1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2018 was Alpine Woods Capital Investors, an estimated $668K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2018 was Advisory Services Network, an estimated $1.92M sold.
Based on aggregated 13F filings for Q4 2018.